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Some evidence indicates that nitric oxide (NO) contributes to inﬂammation, while other evidence supports the opposite
conclusion. To clarify the role of NO in inﬂammation, we studied carrageenin-induced pleurisy in rats treated with an NO
donor (NOC-18), a substrate for NO formation (L-arginine), and/or an NO synthase inhibitor (S-(2-aminoethyl) isothiourea or
N
G-nitro-L-arginine). We assessed inﬂammatory cell migration, nitrite/nitrate values, lipid peroxidation and pro-inﬂammatory
mediators. NOC-18 and L-arginine reduced the migration of inﬂammatory cells and edema, lowered oxidative stress, and
normalized antioxidant enzyme activities. NO synthase inhibitors increased the exudate formationand inﬂammatory cell number,
contributed to oxidative stress, induced an oxidant/antioxidant imbalance by maintaining high O
−
2 , and enhanced the production
of pro-inﬂammatory mediators. L-arginine and NOC-18 reversed the proinﬂammatory eﬀects of NO synthase inhibitors, perhaps
by reducing the expression of adhesion molecules on endothelial cells. Thus, our results indicate that NO is involved in blunting—
not enhancing—the inﬂammatory response.
1.Introduction
Inﬂammation is a protective process essential for the preser-
vation of the integrity of organisms in the event of physical,
chemical, or infectious damage. Acute inﬂammation, which
is characterized by pain, heat, redness, and swelling, involves
acomplexseriesofeventsincludingvasodilatation,increased
permeability, ﬂuid exudation, and migration of leukocytes to
the site of inﬂammation [1].
At the site of an inﬂammatory reaction, the injured
vascular endothelial cells and the emigrated leukocytes
synthesize and release an intricate cascade of inﬂamma-
tory mediators including nitric oxide (NO). NO is an
oxidant synthesized de novo in cells from L-arginine by
isoforms of NO synthase (NOS), including neuronal NOS
(nNOS or NOS1), inducible NOS (iNOS or NOS2), and
endothelial NOS (eNOS or NOS3) [2]. Generally, nNOS
and eNOS are constitutively expressed, whereas iNOS is
induced in response to inﬂammatory-like stimuli and is
capable of sustained production of high levels of NO that
predominate during inﬂammation [2, 3]. Although the
cytostatic/cytocidal activity of NO is part of the host defense
mechanism, the excessive or inappropriate production of
NO can damage tissue, possibly through the formation of
peroxynitrite (ONOO−), a potent oxidizing and nitrating
agent, via the coupling of NO with superoxide anion (O2
−)
[4, 5]. NG-monomethyl-L-arginine (L-NMMA), which is an
arginine analogue that competitively inhibits the constitutive
isoforms of NOS (cNOS: eNOS and nNOS) and iNOS,
signiﬁcantly reduced NO levels and concomitantly reduced
synovial inﬂammation and tissue damage in streptococcal
cell wall (SCW)-induced arthritis [6] and adjuvant arthritis2 Mediators of Inﬂammation
[7] in rodents. Furthermore, NO-mediated production of
ONOO− in humans occurs in oxidative processes associated
with atherogenesis [8] and acute lung injury [9]. Although
this evidence suggests that NO plays a pro-inﬂammatory
role, some reports contradict this ﬁnding. For example, the
stimulation of endogenous NO production or exogenous
administration of NO-donating compounds often blunts the
ultimate expression of tissue injury at both the molecular
and functional levels in cerebrovascular [10], hepatic [11],
splanchnic [12], renal [13], pulmonary [14], myocardial
[15],inﬂammatory,andischemia/reperfusioninjurymodels.
Interestingly, this NO-dependent protective eﬀect occurs in
processes with increased rates of O2
− production and for
which oxidant injury plays an etiological role [10, 11].
Carrageenin (Cg)-induced pleurisy in rats is a well-
characterized experimental model of acute inﬂammation
that permits the quantiﬁcation and correlation of both
exudate and cellular migration with changes in other inﬂam-
matory parameters [16]. In this model, polymorphonuclear
leukocytesarethepredominantcelltypefor12hoursafterCg
injection; then, they are replaced by migrating mononuclear
cells that diﬀerentiate into macrophages and dominate the
reaction until resolution at 48 hours [17, 18]. Thus, this
model is suitable for studying the relationships among
migrating cells, exudates, NO, pro-inﬂammatory cytokines,
and chemokines.
The maintenance of leukocyte recruitment during
inﬂammation requires intercellular communication between
inﬁltrating leukocytes and the endothelium. These events are
mediated by early response cytokines such as interleukin-1β
(IL-1β)a n dt u m o rn e c r o s i sf a c t o r - α (TNF-α), cell-surface
adhesion molecules, and chemotactic molecules such as
chemokines [19].
Chemokines are a family of structurally related glycopro-
teins with potent leukocyte activation and/or chemotactic
activity. Most chemokines are produced in response to
inﬂammatory stimuli, such as the early-response cytokines,
TNF-α,I L - 1 β, C5a, leukotriene B4, and interferons
[20]. Monocyte chemoattractant protein-1 (MCP-1) is a
chemokine that attracts monocytes and neutrophils both in
vitro and in vivo, and it appears to be a key part of leukocyte
emigration by promoting the transition from leukocyte
rolling to adhesion on the endothelial surface [21].
In the present study, we analyzed the involvement of
NO on inﬂammatory cell migration, nitrite/nitrate values,
lipid peroxidation, and pro-inﬂammatory mediators (TNF-
α,I L - 1 β,M C P - 1a n dO 2
−) in Cg-induced pleurisy in rats by
administering NOC-18 (a donor of NO) [22], L-arginine (a
substrate for NO formation), S-(2-aminoethyl) isothiourea
(AE-ITU: an inhibitor of iNOS) [23], and NG-nitro-L-
arginine (L-NNA: an inhibitor of cNOS and iNOS) [24]i n
combination with Cg injection.
2.MaterialsandMethods
2.1. Reagents. S-(2-aminoethyl) isothiourea (AE-ITU), NG-
nitro-L-arginine (L-NNA), and 1-Hydroxy-2-oxo-3,3-bis(2-
aminoethyl)-1-triazene (NOC-18) were purchased from
Dojindo (Kumamoto, Japan). Unless otherwise noted, all
other chemicals used were of the purest grade and obtained
from Sigma Chemical (St. Louis, MO, USA).
2.2. Animals. Male Wistar rats (Japan SLC, Shizuoka, Japan)
weighing150to170gwereusedinthisstudy.Foodandwater
were available ad libitum. The light cycle was automatically
controlled (12-hour light, 12-hour dark), and the room
temperature was maintained at 23 ± 1◦C. For 4 days
prior to the experiments, animals were housed under these
conditions to allow for acclimatization. All experiments
were performed according to the Guidelines for Animal
Experimentation of Nagoya University.
2.3. Induction of Cg-Induced Pleurisy and Measurement
of Inﬂammatory Parameters. Animals were slightly anes-
thetized with diethyl ether; subsequently, 0.15 mL of
physiological saline solution or 1% (w/v) λ-Cg (Sigma
Chemical, St. Louis, MO, USA) suspended in physiological
saline was injected into the right pleural cavity. After 2, 6,
12, 24, 36, 54, and 72 hours, animals were sacriﬁced via
exsanguination from the abdominal aorta under deep ether-
anesthesia. Pleural exudate from each animal was harvested
by washing the pleural cavity with 1mL of 3.15% (w/v)
sodium citrate in physiological saline as an anticoagulant.
Exudates contaminated with blood were rejected. Exudate
volumes were measured, and the volume injected into the
pleural cavity (1mL) was subtracted from the total volume
recovered. Exudate samples were then centrifuged at 800 × g
for 10 minutes, after which cell pellets were resuspended in
saline. To estimate the number of cells in each sample, cells
were stained with trypan blue and then counted by using
an optical microscope with a Burker counting chamber. In
some experiments, diﬀerential cell counts were determined
in smears by May-Grunwald staining.
2.4. Treatments. In the ﬁrst set of experiments, rats (6 to
8 rats per group) received an intrapleural Cg injection
immediately after intrapleural administration of vehicle
(saline), 10mg/kg of AE-ITU, 1mg/kg of L-NNA, 10mg/kg
of NOC-18, or 30mg/kg of L-arginine. The doses of AE-
ITU [25], L-NNA [26], NOC-18 [27], and L-arginine [27]
were based on previous reports from the literature with
modiﬁcation of the administration route. Five additional
groups of rats (5 rats per group) were treated with 10mg/kg
of AE-ITU, 1mg/kg of L-NNA, 10mg/kg of NOC-18, or
30mg/kg of L-arginine, but they did not receive the Cg
injection. After 6 hours, the rats were sacriﬁced, and pleural
exudates were collected and processed as described above.
In the second set of experiments, rats (6 rats per
group)treatedwithAE-ITU(10mg/kg)orL-NNA(1mg/kg)
immediately before Cg injection also received intrapleural
injections of NOC-18 (10mg/kg) or L-arginine (30mg/kg).
NOC-18 and L-arginine treatments were performed simul-
taneously with NOS inhibitor injection. Animals were
sacriﬁced 6 hours after the induction of pleurisy, and
pleural exudates were collected and processed. In each set of
experiments, the control group received only vehicle(s) via
the appropriate route of administration.Mediators of Inﬂammation 3
2.5. Nitrite/Nitrate Assay. The amount of nitrites and
nitrates, which are indicators of NO synthesis, in the
supernatant of centrifuged exudate was measured with a
colorimetric commercial kit (Nitrite/Nitrate Assay Kit-C II;
Dojindo), according to the manufacturer’s instructions.
2.6. Malondialdehyde Assay. We used the thiobarbituric acid
reactive substances (TBARS) method as an index of lipid
peroxidation for analyzing malondialdehyde (MDA) prod-
ucts during an acid-heating reaction, as previously described
by Draper and coworkers [28]. Brieﬂy, the supernatant of
200μL of centrifuged exudates was mixed with 1mL of 10%
trichloroacetic acid and 1mL of 0.67% thiobarbituric acid;
the samples were then heated in a boiling water bath for 30
minutes. TBARS levels were determined by absorbance at
532nm and expressed as malondialdehyde equivalents.
2.7. Assay for TNF-α,I L - 1 β, and MCP-1. TNF-α,I L - 1 β and
MCP-1 were measured in the supernatant of centrifuged
exudates by enzyme-immunoassay kits (BioSource Interna-
tional,Camarillo,CA,USA),accordingtothemanufacturer’s
instructions.
2.8. Total Antioxidant Status Assay. The total antioxidant
status (TAOS) is an indication of O2
− and other oxidant
species. The TAOS of the supernatant of centrifuged exu-
date was determined as previously described [29]. Brieﬂy,
the reaction mixture consisted of (ﬁnal concentrations):
20μL2 , 2  -azino-bis(3-ethylbenzthiazoline-6-sulfonic acid)
(ABTS; 2mM), 10μL horseradish peroxidase (30mU/mL),
20μLH 2O2 (0.1mM),40μLphosphate-buﬀeredsaline(PBS;
in mM: 137 NaCl, 8.10 Na2HPO4, 2.68 KCl, 1.47 KH2PO4,
pH7.40), and10μLof samplein atotal volume of100μLpe r
wellof 96-well plates. Thereaction, whichwasinitiated upon
the addition of H2O2,w a sc o n d u c t e da t3 7 ◦C. The increase
in absorbance at 405nm, a reﬂection of 2,2
 -azino-bis(3-
ethylbenzthiazoline-6-sulfonic acid) radical cation (ABTS+)
accumulation, was measured by using a microplate reader
(Molecular Devices, Crawley, UK).
2.9. Statistical Analysis. All data are expressed as the mean ±
standard error of the mean (S.E.M.). The statistical analysis
was conducted by using ANOVA followed by the Bonferroni
t-test. Diﬀerences between groups were considered statisti-
cally signiﬁcant when P<. 05.
3. Results
3.1. Time Course of Exudate Formation and Cellular Inﬁltra-
tion. ThepleuralcavityofcontrolratsthatdidnotreceiveCg
or drugs contained no exudates and 2.9 ± 0.5 × 106 cells per
rat(n = 5),andthesecellswerepredominantlymononuclear
(>95%). Injection of 0.15mL of 1% Cg into the pleural
cavity of rats caused an inﬂammatory response characterized
by exudate formation and cell migration (Figure 1). The
exudate volume and the number of leukocytes in the pleural
cavity increased with time, reaching a maximum at 24 hours
(2.11 ± 0.08mL/rat and 108.6 ± 7.5 × 106 cells/rat, n = 8)
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Figure 1: Time course of rat Cg pleurisy. Exudate volume (a) and
leukocyte inﬁltration (b) were evaluated at diﬀerent time points
after Cg injection. The values are expressed as mean ± S.E.M. of
6t o8r a t s .
and decreasing at 54 hours (0.46 ± 0.07mL/rat and 43.3
± 6.1 × 106 cells/rat, n = 7). Both levels returned to the
background levels by 72 hours. Diﬀerential cell counts of
leukocytes that migrated into the pleural cavity showed that
polymorphonuclear leukocytes dominated the early phase (2
hours) of the reaction (89% polymorphonuclear leukocytes
and 11% mononuclear leukocytes) and were then replaced at
54 hours by mononuclear leukocytes (26% polymorphonu-
clear leukocytes and 74% mononuclear leukocytes).
3.2. Time Course of Nitrite/Nitrate Production in the Exudate
of Cg-Induced Rat Pleurisy. We measured the levels of
nitrite/nitrate in the pleural exudate of rats at diﬀerent time
points after the induction of pleurisy. As shown in Figure 2,
nitrite/nitratewasdetectableinthepleuralexudateat2hours
and peaked at 6 hours after Cg injection before gradually
decreasing.
3.3. Eﬀects of AE-ITU, L-NNA, NOC-18, or L-Arginine on
Cg-Induced Rat Pleurisy. To determine the contribution of
NO to the inﬂammatory response, we measured the eﬀects
of AE-ITU (selective iNOS inhibitor), L-NNA (non-selective
NOS inhibitor), NOC-18 (a donor of NO), or L-arginine (a
substrate for NO formation) administered directly into the4 Mediators of Inﬂammation
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Figure 2: Time course of nitrite/nitrate levels. The nitrite/nitrate
assay was performed in rat pleural exudates collected from control
rats (C) or Cg-treated rats at 2, 6, 12, 24, 36, 54, and 72 hours after
pleural injection. The values are expressed as mean ± S.E.M. of 6 to
8r a t s .
pleural cavity immediately before Cg injection. The exudate
formation and inﬂammatory cell number were signiﬁcantly
increased with the addition of AE-ITU (both P<. 01)
(Figures 3(a) and 3(b)) or L-NNA (P<. 05 and P<. 01,
resp.). Both the Cg + AE-ITU and Cg + L-NNA groups
showed a marked reduction in the levels of nitrite/nitrate as
compared to the Cg group (both P<. 01) (Figure 3(c)). No
statistical diﬀerences were observed between the Cg + AE-
ITU and Cg + L-NNA groups.
In a parallel experiment, the exudate volume and the
number of inﬂammatory cells were signiﬁcantly reduced by
the addition of NOC-18 (P<. 05 and P<. 01) (Figure 4(a))
or L-arg (both P<. 01) (Figure 4(b)). Both the Cg + NOC-
18 and Cg + L-arg groups had markedly increased levels of
nitrite/nitrate as compared to the Cg group (both P<. 01)
(Figure 4(c)).
3.4. Eﬀects of NOC-18, or L-Arginine on the Inﬂuence of
AE-ITU or L-NNA on Cg-Induced Rat Pleurisy. Next, we
determined if the changes in the NO level were responsible
for the exacerbation of inﬂammation at 6 hours by AE-ITU
and L-NNA. When NOC-18 was injected in rats simulta-
neously treated with AE-ITU or L-NNA, the exacerbating
inﬂuences of these NOS inhibitors were completed reversed
(Figure 5). Similar results were obtained with L-arginine
(data not shown).
3.5. Eﬀects of AE-ITU, L-NNA, NOC-18 or L-Arginine on
Pleural Inﬂammation in the Absence of Cg. To show that
AE-ITU, L-NNA, NOC-18 or L-arginine did not aﬀect
inﬂammation simply as a result of direct irritation, these
compounds or vehicle were injected into the pleural cavity in
the absence of Cg. None of these compounds caused exudate
formation or an increase in the cellular inﬂux (data not
shown).
3.6. Eﬀect of AE-ITU, L-NNA, NOC-18, or L-Arginine on
Malondialdehyde Content in Pleural Exudates. The MDA
levels in the Cg (P<. 01), Cg + AE-ITU (P<. 01) and
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Figure 3: Eﬀects of AE-ITU and L-NNA on rat Cg pleurisy and
nitrite/nitrate levels. AE-ITU or L-NNA was injected into the
pleuralcavityimmediatelybeforeCginjection.Theexudatevolume
(a), cell number (b), and nitrite/nitrate levels (c) in the pleural
exudates were determined 6 hours after Cg injection. Data are
expressed as mean ± S.E.M. of 6 to 8 rats.
∗P <. 05,
∗∗P <. 01
as compared to the Cg group.Mediators of Inﬂammation 5
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Figure 4: Eﬀects of NOC-18 and L-arginine on rat Cg pleurisy
and nitrite/nitrate levels. NOC18 or L-arginine was injected into
the pleural cavity immediately before Cg injection. The exudate
volume (a), cell number (b), and nitrite/nitrate levels (c) in the
pleural exudates were determined 6 hours after Cg injection. Data
are expressed as mean ± S.E.M. of 6 to 8 rats.
∗P <. 05,
∗∗P <. 01
as compared to the Cg group.
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Figure 5: Eﬀects of NOC-18 on the inﬂuence of AE-ITU and L-
NNA on exudate volume (empty columns) and cell inﬁltration
(ﬁlled columns) 6 hours after Cg challenge. Each column represents
the mean ± S.E.M. of 6 rats.
∗P <. 05,
∗∗P <. 01 as compared to
the vehicle plus vehicle; ##P <. 01 as compared to the vehicle plus
AE-ITU;
††P <. 01 as compared to the vehicle plus L-NNA.
Cg + L-NNA groups (P<. 01) were signiﬁcantly increased
as compared to the control group (Figure 6). MDA levels in
the Cg + AE-ITU and Cg + L-NNA groups were increased
as compared to that of the Cg group (both P<. 01). On the
other hand, the Cg + NOC-18 and Cg + L-arg groups had
a decreased MDA level as compared to the Cg group (both
P<. 01). MDA levels in the Cg + NOC-18 and Cg + L-arg
groups were similar to that of the control group.
3.7. Eﬀect of AE-ITU, L-NNA, NOC-18, or L-Arginine on
the Release of TNF-α,I L - 1 β, and MCP-1. We measured the
levelsof TNF-α(Figure7(a)),IL-1β (Figure7(b)),andMCP-
1 (Figure 7(c)) in the pleural exudates. The Cg group had
ah i g h e rl e v e lo fT N F - α as compared to the control group
(P<. 01). The Cg + AE-ITU and Cg + L-NNA groups had
the highest levels of TNF-α in comparison to the Cg group
(both P<. 05) and the control group (both P<. 01). The
levels of TNF-α in the Cg + NOC-18 and Cg + L-arg groups
were lower than that of the Cg group (both P<. 01) but
higher than that of the control group (both P<. 01). The
Cg (P<. 01), Cg + AE-ITU (P<. 01) and Cg + L-NNA
groups (P<. 01) had increased IL-1β levels as compared to
the control group, while the Cg + NOC-18 (P<. 01) and
Cg + L-arg groups (P<. 05) had reduced IL-1β levels as
comparedtotheCggroup.However,intheCg+L-arggroup,
the level of IL-1β was higher compared to the control group
(P<. 05), while there was no diﬀerence between the IL-1β
levelsoftheCg+NOC-18andcontrolgroups.LiketheTNF-
α and IL-1β levels, the MCP-1 levels in the Cg + AE-ITU and
Cg + L-NNA groups were increased as compared to the Cg
group (both P<. 05). The MCP-1 levels of the Cg + NOC-
18 and Cg + L-arg groups were signiﬁcantly lower than that6 Mediators of Inﬂammation
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Figure 6: Eﬀect of AE-ITU, L-NNA, NOC-18, and L-arginine on
malondialdehyde (MDA) content in the pleural exudates 6 hours
after Cg challenge. Data are expressed as mean ± S.E.M. of 6 to
8r a t s .
∗∗P <. 01 as compared to control group; ##P <. 01 as
compared to Cg group.
of the Cg group (both P<. 05) and signiﬁcantly higher than
that of the control group (both P<. 01).
3.8. Eﬀect of AE-ITU, L-NNA, NOC-18 or L-Arginine on
TAOSActivityinPleuralExudates. TheCggrouphadalower
l e v e lo fT A O Sa c t i v i t ya sc o m p a r e dt ot h ec o n t r o lg r o u p( P<
.01) (Figure 8). The Cg + AE-ITU and Cg + L-NNA groups
hadthelowestlevelofTAOSactivityincomparisontotheCg
group (both P<. 01) and the control group (both P<. 01).
In contrast, the TAOS activity levels in the Cg + NOC-18 and
Cg + L-arg groups were increased in comparison to the Cg
group(bothP<. 01)andsimilartothatofthecontrolgroup.
4. Discussion
Nitric oxide is a signaling molecule responsible for diverse
physiological and pathophysiological processes. Until now,
the prevailing hypothesis about NO is that it contributes
to toxicant-induced pleural inﬂammation and injury [30,
31]. The present study suggests a diﬀerent role for NO
in the rat pleural inﬂammatory response induced by Cg.
We found that the administration of an NO donor (NOC-
18) or NO substrate (L-arginine) reduced the migration of
inﬂammatory cells and edema formation, lowered oxidative
stress, and normalized antioxidant enzyme activities. The
action of NO here was diﬀerent from its actions elicited
by other pleura and/or lung inﬂammatory stimuli such as
lipopolysaccharide(LPS),des-Arg9-bradykinin,orsubstance
P[ 32–34]. Although several studies have described NO as
a mediator of the inﬂammatory response—for example, by
stimulating production of inﬂammatory cytokines and per-
oxynitrite (ONOO−)[ 4, 5]—beneﬁcial eﬀects of NO during
inﬂammatory insult have also been reported [10–15, 25, 27].
We observed a reduction in the number of inﬂammatory
cells within the pleural cavity in the Cg + NOC-18 and
Cg + L-arg groups as compared to the Cg group. The
speciﬁc action of NO on inﬂammatory cells is unknown,
but we suggest that NOC-18 and L-arginine may reduce
the expression of endothelial cell adhesion molecules and
consequently reduce the inﬂammatory cell migration into
the pleural space. Furthermore, NO was reported to be an
important molecule for blocking the endothelium-leukocyte
interaction [35, 36]. Apoptosis of inﬂammatory cells dur-
ing the inﬂammatory process by Cg injection through
NO activation of death domains is another hypothesis to
explain the reduced number of inﬂammatory cells within
the pleural cavity in the Cg + NOC-18 and Cg + L-
arg groups, due to the involvement of NO in apoptosis
[36, 37]. By contrast, L-NNA, an inhibitor of cNOS and
iNOS, or AE-ITU, a selective iNOS inhibitor, resulted in
an increased level of leukocytes as compared to the Cg
group. Therefore, although Cg itself increased nitrite/nitrate
formation, decreasing the nitrite/nitrate formation with L-
NNA or AE-ITU actually exacerbated the inﬂammatory
response in terms of leukocyte levels and exudate volume.
The eﬀects of the NOS inhibitors on leukocyte migration
appear to be a consequence of the inhibition of the L-
arginine/NOpathway,becausetheenhancementofleukocyte
migration was reversed by cotreatment with L-arginine and
NOC-18. These data help to explain the positive eﬀects of
an NO donor or substrate in decreasing the inﬂammatory
response by lowering cell recruitment into the inﬂammatory
site. However, it is possible that the contribution of NO to
the development of the inﬂammatory reaction depends on
the intensity of tissue injury and integrity of the structures
involved in the process. Future eﬀorts also will undoubtedly
focus on attempting to decipher the diﬀerences in the time
course of pharmacological assays, doses, and the observation
time intervals.
The fact that the IC50 of L-NNA for the inhibition
of eNOS is around 10 times lower than that for iNOS
inhibition [24] suggests that, at low doses, L-NNA is
inhibiting predominantly the eNOS isoform. This, together
with the demonstration that AE-ITU, a selective inhibitor
of iNOS [23], enhanced the leukocyte migration, suggests
that during the inﬂammatory process, NO, which modulates
the leukocyte migration, is synthesized by either eNOS or
iNOS. There is evidence in the literature that during the
inﬂammatory process the expression of eNOS or its activity
is enhanced [38] and iNOS is induced [39]. Additionally,
other authors have demonstrated that NO downmodulates
the leukocyte migration during the inﬂammatory process
and that it is released by both NOS isoforms. Animals treated
with selective iNOS inhibitors (aminoguanidine, 1400W, L-
NIL and AE-ITU) or a selective eNOS inhibitor (L-NIO)
present enhanced leukocyte migration to inﬂammatory sites
[25, 27, 40, 41]. Furthermore, the NO donors, SIN-1,
spermine-NO, sodium nitroprusside, and NOC-18, inhibit
both the adhesion and leukocyte migration induced byMediators of Inﬂammation 7
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Figure 7: Eﬀects of AE-ITU, L-NNA, NOC-18 and L-arginine on the release of cytokines. Tumor necrosis factor-α (TNF-α) (a), interleukin-
1β (IL-1β) (b) and monocyte chemoattractant protein-1 (MCP-1) (c) levels in the pleural exudates 6 hours after Cg challenge. Data are
expressed as mean ± S.E.M. from 6 to 8 rats.
∗P <. 05,
∗∗P <. 01 as compared to control group; #P <. 05, ##P <. 01 as compared to Cg
group.
LPS, IL-1, Cg, or ischemia/reperfusion [27, 42–45]. On the
other hand, there are some studies that contradict these
reports and our own ﬁndings. Animals treated with NOS
inhibitors (L-NAME, L-NIL, L-NMMA, or aminoguanidine)
or iNOS knockout mice present a reduction in the leukocyte
migration induced by staphylococcal enterotoxin B (SEB),
zymosan, SWC, or Cg [40, 46–48]. It has been suggested that
these apparently conﬂicting data could be a consequence of
vasoconstriction, leading to reduced local blood ﬂow, due
to the use of high doses and/or systemic administration of
the drugs [25, 27]. However, decreased blood ﬂow in the
microcirculation cannot completely explain the reduction in
leukocyte migration induced by zymosan and Cg in iNOS
knockout mice [46, 47] ,w h i c hd on o te x p e r i e n c ec h a n g e si n
blood pressure after the inﬂammatory stimuli injection. We
do not have an explanation for these diﬀerences; however,
i no u rs t u d y ,r a t st r e a t e dw i t hL - N N Ao rA E - I T Ua n d
injected with Cg presented a massive leukocyte migration.
It is important to point out that rats treated with the same
doseofL-NNAdidnotpresentasigniﬁcantincreaseinblood
pressure [26].
Lipid peroxidation is an important marker of oxidative
stress in pleuritis. Cg-induced pleurisy and lipid peroxida-
tion (as analyzed by MDA) have been previously associated
[28]. We found that MDA levels in Cg-injected animals were
increased by NOS inhibitors. Treatment with NOC-18 or L-
arginine reduced the amount of MDA. This result is similar
tothatofMachov´ aandc o w ork ers[49],whoshowedthatNO
treatment inhibited lipid peroxidation in vitro and protected
against cellular damage and cytotoxicity. NO has also been
described as a scavenger of other far more toxic radicals
and, therefore, an enhancer of defense mechanisms [50].8 Mediators of Inﬂammation
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Figure 8: Eﬀect of AE-ITU, L-NNA, NOC-18, and L-arginine on
total antioxidant status (TAOS) activity in pleural exudates 6 hours
after Cg challenge. Data are expressed as mean ± S.E.M. from 6 to
8r a t s .
∗∗P <. 01 as compared to the control group; ##P <. 01 as
compared to the Cg group.
Consequently, the increased levels of lipid peroxidation were
observed only in the Cg + L-NNA and Cg + AE-ITU groups
but not in the Cg + NOC-18 and Cg + L-arg groups.
There is substantial evidence that the pro-inﬂammatory
cytokines TNF-α and IL-1β propagate the extension of a
local or systemic inﬂammatory process [51, 52]. We conﬁrm
here that the inﬂammatory process induced by Cg injection
into the pleural cavity leads to substantial increases in the
levels of TNF-α and IL-1β in the exudate. Interestingly, the
inhibition of NO synthesis by L-NNA or AE-ITU further
increased the levels of these two pro-inﬂammatory cytokines
in the exudate, whereas NOC-18 or L-arginine did not cause
a further increase. In support of this observation, others
have shown that inhibition of NO synthesis by L-NAME in
rats subjected to hepatic ischemia/reperfusion enhanced the
expression of TNF-α and IL-1β mRNA in the ischemic lobes
of liver and increased plasma levels of TNF-α and IL-1β [53].
Previous experiments have also shown that the NO donor
SNAP dose dependently reduced the amounts of TNF-α and
IL-1β produced by activated macrophages [54].
MCP-1 is a monocyte chemotactic factor that exerts
potent and speciﬁc chemoattractant activity on both mono-
cytes and neutrophils [21]. Monocytes and, to a lesser extent,
granulocytessecreteMCP-1inresponsetocytokines,viruses,
bacterialendotoxins,andmitogens[55].Invitrostudieshave
shown that NO donors (NONOate compounds) inhibit the
expression and production of MCP-1 in cytokine-activated
human endothelial cells [56]. In addition, inhibition of
endogenous NO synthesis by L-NNA increased endothelial
MCP-1 mRNA expression and resulted in a marked increase
in monocyte chemotactic activity [57], suggesting that NO
modulates MCP-1 expression and activity in vitro. In agree-
ment with these studies, we found that MCP-1 production in
pleural exudates is downregulated by NOC-18 or L-arginine
andupregulatedbyNOSinhibitors.Collectively,theseresults
suggest that a compensatory increase in NO production
at inﬂammatory sites critically regulates the severity of the
inﬂammatory response by moderating the levels of such
potently pro-inﬂammatory mediators as TNF-α,I L - 1 β,a n d
MCP-1. Additionally, the lower levels of TNF-α,I L - 1 β,a n d
MCP-1 in the Cg + NOC-18 and Cg + L-arg groups conﬁrm
the eﬃcacy of treatment with an NO donor or substrate,
leading us to hypothesize that NO is involved in blunting the
inﬂammatory response.
We measured TAOS activity as an indirect indication
of the formation of O2
− and other oxidant species. This
assay is based on the principle that oxidants formed during
inﬂammation react with antioxidants such as glutathione,
ascorbic acid, and α-tocopherol [29] and reduce the antioxi-
dant capacity of inﬂammatory exudates [58]. This index of
O2
− and other oxidant species was increased in the Cg +
NOC-18 and Cg + L-arg groups in comparison with the Cg
group, and these values were generally similar to those of
the control group. Thus, the Cg + NOC-18 and Cg + L-arg
groups appeared to downregulate O2
− generation to some
degree. In contrast, the TAOS activities of both the Cg + L-
NNA and Cg + AE-ITU groups were lower than those of
the Cg and control groups, suggesting that O2
− generation
was enhanced in the absence of NO. O2
− is produced by
polymorphonuclear leukocytes and macrophages from the
enzyme activity of NADPH oxidase and xanthine oxidase at
inﬂammatory sites. Both enzyme systems contain a heme
prosthetic group with which NO can react to inhibit O2
−
release [59]. Therefore, inhibiting NO removes the brakes
on O2
− production. In support of this notion, others have
shown that NO generation reduces O2
− levels, while its
inhibition increases O2
− production both in vitro and in
vivo [60, 61]. As O2
− has been associated with tissue damage
and loss of function during inﬂammatory episodes [62], it
is conceivable that one of the contributors to an enhanced
inﬂammatory response, consequent to NOS inhibition, is
O2
− generation. Indeed, elevated levels of O2
− increase
TNF-α release from macrophages [63] and neutrophils
and neutrophil activation through a Toll-like receptor 4-
dependent mechanism [64]. Increased levels of O2
− also
activate NF-κB[ 65], which may account for the increased
production of IL-1β. Although no direct eﬀects of O2
− on
the upregulation of IL-1β have been demonstrated, an O2
−
dismutase mimetic, M40403, signiﬁcantly reduced NF-κB
DNA binding [66]a n dI L - 1 β production in inﬂamed lungs
[67]. Moreover, in endothelial cells, adenovirus-mediated
expression of O2
− dismutase suppressed TNF-α-induced
MCP-1 mRNA expression and MCP-1 protein secretion
[68]. Therefore, a disturbance in the balance between NO
and O2
− p r o d u c t i o nm a yl e a dt oa ni n c r e a s ei np r o -
inﬂammatory mediators and provide a possible mechanism
for the exacerbation of inﬂammation observed in the present
study.
In summary, we showed that NO supplementation by
NOC-18 or L-arginine reduced Cg-induced pleurisy and
oxidative stress and regulated TNF-α,I L 1 - β,M C P - 1 ,a n d
O2
− levels at the inﬂammatory site. The NOS inhibitorsMediators of Inﬂammation 9
exacerbated the inﬂammatory status in the pleural cavity of
Cg-injected rats, contributed to oxidative stress, and induced
a major imbalance between oxidants and antioxidants by
maintaining high O2
− levels, favoring the oxidant side.
Supplementation with NO may be a promising treatment
for inﬂammatory diseases that involve oxidative stress, but
further investigations are needed to conﬁrm this hypothesis.
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